BioPorto Advances U.S. Adult NGAL Study with Positive Preliminary Results
Event summary
- BioPorto completed preliminary analysis of its U.S. adult NGAL Cutoff Study, supporting the primary endpoint for assessing acute kidney injury (AKI) risk.
- Patient enrollment was completed in October 2025, with database lock finalized in March 2026.
- FDA Pre-submission package expected by the end of March 2026 to guide the subsequent Validation Study.
- Results align with prior pediatric study findings, which led to FDA clearance in late 2023.
The big picture
BioPorto's progress in the adult NGAL study reinforces its strategy of leveraging biomarker diagnostics to improve early intervention in acute kidney injury. The alignment with prior pediatric results suggests a scalable regulatory approach, though success in the adult market will depend on FDA alignment and clinical adoption. The diagnostics sector continues to prioritize actionable biomarkers, positioning BioPorto as a key player in this high-need area.
What we're watching
- Regulatory Pathway
- How FDA feedback on the Pre-submission will shape the design of the Validation Study.
- Clinical Validation
- Whether the adult NGAL assay will replicate the success seen in the pediatric segment.
- Market Expansion
- The pace at which BioPorto can commercialize the NGAL test for adult AKI risk assessment post-approval.
Related topics